Carcinogenicity of antihypertensive therapy

Current Hypertension Reports

Volumn 4, Issue 3, 2002, Pages 195-201

  Grossman, Ehud ^b   Messerli, Franz H ^a   Goldbourt, Uri ^b  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CARCINOGEN; RESERPINE;

ANIMAL; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; HYPERTENSION; LONGITUDINAL STUDY; NEOPLASM; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BREAST NEOPLASMS; CARCINOGENS; HUMANS; HYPERTENSION; LONGITUDINAL STUDIES; NEOPLASMS; NEOPLASMS, RADIATION-INDUCED; RANDOMIZED CONTROLLED TRIALS; RESERPINE;

EID: 0036618180     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-002-0007-4     Document Type: Article

References (103)

1. MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. BMJ (Clin Res Ed) 1985, 291: 97-104.
2. The Australian therapeutic trial in mild hypertension. Report by the management committee. Lancet 1980, 1: 1261-1267.
3. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ 1992, 304: 405-412.
4. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991, 265: 3255-3264.
5. Staessen J, Bulpitt C, Clement D, et al.: Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ 1989, 298: 1552-1556.
6. Grossman E, Messerli FH, Boyko V, Goldbourt U: Is there an association between hypertension and cancer mortality. Am J Med 2002, In press.
7. Williams RR, Feinleib M, Connor RJ, Stegens NL: Case-control study of antihypertensive and diuretic use by women with malignant and benign breast lesions detected in a mammography screening program. J Natl Cancer Inst 1978, 61: 327-335.
8. Fraser GE, Phillips RL, Beeson WL: Hypertension, antihypertensive medication and risk of renal carcinoma in California Seventh-Day Adventists. Int J Epidemiol 1990, 19: 832-838.
9. Grove JS, Nomura A, Severson RK, Stemmermann GN: The association of blood pressure with cancer incidence in a prospective study. Am J Epidemiol 1991, 134: 942-947.
10. Suadicani P, Hein HO, Gyntelberg F: Is the use of antihypertensives and sedatives a major risk factor for colorectal cancer? Scand J Gastroenterol 1993, 28: 475-481.
11. McLaughlin JK, Chow WH, Mandel JS, et al.: International renal-cell cancer study. VIII. Role of diuretics, other antihypertensive medications and hypertension. Int J Cancer 1995, 63: 216-221.
12. Chow WH, McLaughlin JK, Mandel JS, et al.: Risk of renal cell cancer in relation to diuretics, antihypertensive drugs, and hypertension. Cancer Epidemiol Biomarkers Prev 1995, 4: 327-331.
13. Peeters PH, van Noord PA, Hoes AW, Grobbee DE: Hypertension, antihypertensive drugs, and mortality from cancer among women. J Hypertens 1998, 16: 941-947.
14. Rosenberg L, Rao RS, Palmer JR, et al.: Calcium channel blockers and the risk of cancer. JAMA 1998, 279: 1000-1004.
15. Reserpine and breast cancer. Lancet 1974, 2: 669-671.
16. Mellemgaard A, Moller H, Olsen JH: Diuretics may increase risk of renal cell carcinoma. Cancer Causes Control 1992, 3: 309-312.
17. Kreiger N, Marrett LD, Dodds L, et al.: Risk factors for renal cell carcinoma: results of a population-based case-control study. Cancer Causes Control 1993, 4: 101-110.
18. Mellemgaard A, Niwa S, Mehl ES, et al.: Risk factors for renal cell carcinoma in Denmark: role of medication and medical history. Int J Epidemiol 1994, 23: 923-930.
19. Finkle WD, McLaughlin JK, Rasgon SA, et al.: Increased risk of renal cell cancer among women using diuretics in the United States. Cancer Causes Control 1993, 4: 555-558.
20. Hiatt RA, Tolan K, Quesenberry CP Jr: Renal cell carcinoma and thiazide use: a historical, case-control study (California, USA). Cancer Causes Control 1994, 5: 319-325.
21. Weinmann S, Glass AG, Weiss NS, et al.: Use of diuretics and other antihypertensive medications in relation to the risk of renal cell cancer. Am J Epidemiol 1994, 140: 792-804.
22. Pahor M, Guralnik JM, Salive ME, et al.: Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996, 9: 695-699.
23. Pahor M, Guralnik JM, Ferrucci L, et al.: Calcium-channel blockade and incidence of cancer in aged populations. Lancet 1996, 348: 493-497.
24. Fitzpatrick AL, Daling JR, Furberg CD, et al.: Use of calcium channel blockers and breast carcinoma risk in postmeno-pausal women. Cancer 1997, 80: 1438-1447.
25. Dyer AR, Stamler J, Berkson DM, et al.: High blood-pressure: a risk factor for cancer mortality? Lancet 1975, 1: 1051-1056.
26. Grossman E, Messerli FH, Goldbourt U: Antihypertensive therapy and the risk of malignancies. Eur Heart J 2001, 22: 1343-1352.
27. McCredie M, Stewart JH: Risk factors for kidney cancer in New South Wales, Australia. II. Urologic disease, hypertension, obesity, and hormonal factors. Cancer Causes Control 1992, 3: 323-331.
28. Andersson OK, Almgren T, Persson B, et al.: Survival in treated hypertension: follow up study after two decades. BMJ 1998, 317: 167-1671.
29. Armstrong B, Stevens N, Doll R: Retrospective study of the association between use of rauwolfia derivatives and breast cancer in English women. Lancet 1974, 2: 672-675.
30. Heinonen OP, Shapiro S, Tuominen L, Turunen MI: Reserpine use in relation to breast cancer. Lancet 1974, 2: 675-677.
31. Armstrong B, Skegg D, White G, Doll R: Rauwolfia derivatives and breast cancer in hypertensive women. Lancet 1976, 2: 8-12.
32. Kodlin D, McCarthy N: Reserpine and breast cancer. Cancer 1978, 41: 761-768.
33. Labarthe DR, O'Fallon WM: Reserpine and breast cancer. A community-based longitudinal study of 2,000 hypertensive women. JAMA 1980, 243: 2304-2310.
34. Curb JD, Hardy RJ, Labarthe DR, et al.: Reserpine and breast cancer in the Hypertension Detection and Follow-Up Program. Hypertension 1982, 4: 307-311.
35. Friedman GD: Rauwolfia and breast cancer: no relation found in long term users age fifty and over. J Chron Dis 1983, 36: 367-370.
36. Newball HH, Byar DP: Does reserpine increase prolactin and exacerbate cancer of prostate? Case control study. Urology 1973, 2: 525-529.
37. Byar DP, Blackard CE: Letters: reserpine and prostatic cancer. Urology 1975, 5: 158-159.
38. Yu MC, Mack TM, Hanisch R, et al.: Cigarette smoking, obesity, diuretic use, and coffee consumption as risk factors for renal cell carcinoma. J Natl Cancer Inst 1986, 77: 351-356.
39. Shapiro JA, Williams MA, Weiss NS, et al.: Hypertension, antihypertensive medication use, and risk of renal cell carcinoma. Am J Epidemiol 1999, 149: 521-530.
40. Prineas RJ, Folsom AR, Zhang ZM, et al.: Nutrition and other risk factors for renal cell carcinoma in postmenopausal women. Epidemiology 1997, 8: 31-36.
41. Heath CW Jr, Lally CA, Calle EE, et al.: Hypertension, diuretics, and antihypertensive medications as possible risk factors for renal cell cancer. Am J Epidemiol 1997, 145: 607-613.
42. Lijinsky W, Reuber MD: Pathologic effects of chronic administration of hydrochlorothiazide, with and without sodium nitrite, to F344 rats. Toxicol Ind Health 1987, 3: 413-422.
43. Loffing J, Loffing-Cueni D, Hegyi I, et al.: Thiazide treatment of rats provokes apoptosis in distal tubule cells. Kidney Int 1996, 50: 1180-1190.
44. Tenenbaum A, Grossman E, Fisman EZ, et al.: Long-term diuretic therapy in patients with coronary disease: increased colon cancer-related mortality over a 5-year follow-up. J Hum Hypertens 2001, 15: 373-379.
45. Tenenbaum A, Motro M, Jonas M, et al.: Is diuretic therapy associated with an increased risk of colon cancer? Am J Med 2001, 110: 143-145.
46. Lilienfeld AM, Chang L, Thomas DB, Levin ML: Rauwolfia derivatives and breast cancer. Johns Hopkins Med J 1976, 139: 41-50.
47. Aromaa A, Hakama M, Hakulinen T, et al.: Breast cancer and use of rauwolfia and other antihypertensive agents in hypertensive patients: a nationwide case-control study in Finland. Int J Cancer 1976, 18: 727-738.
48. Lindholm LH, Anderson H, Ekbom T, et al.: Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial. Lancet 2001, 358: 539-544.
49. Coope J, Warrender TS: Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ (Clin Res Ed) 1986, 293: 1145-1151.
50. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998, 317: 713-720.
51. Zavanella T, Radaelli G, Girotti P, et al.: Evaluation of the tumor-promoting activity of two beta-adrenoreceptor blocking agents, propranolol and atenolol, in liver of Fischer 344 rats. Carcinogenesis 1994, 15: 2531-2539.
52. Ioannides C, Okine L, Parke DV: Effects of beta-adrenoceptor antagonists on the hepatic mixed-function oxygenases in the rat. Br J Pharmacol 1979, 67: 451P-452P.
53. Boyd H, Martin TJ: The effect of propranolol on induction of rat liver tumors by a chemical carcinogen. Mol Pharmacol 1977, 13: 576-578.
54. Gurkalo VK, Zabezhinski MA: On participation of the autonomic nervous system in the mechanisms of chemical carcinogenesis. Neoplasma 1982, 29: 301-307.
55. Hole DJ, Hawthorne VM, Isles CG, et al.: Incidence of and mortality from cancer in hypertensive patients. BMJ 1993, 306: 609-611.
56. Fletcher AE, Beevers DG, Bulpitt CJ, et al.: Cancer mortality and atenolol treatment. BMJ 1993, 306: 622-623.
57. Jick H, Jick S, Derby LE, et al.: Calcium-channel blockers and risk of cancer. Lancet 1997, 349: 525-528.
58. Messerli FH, Grossman E: Antihypertensive agents and the risk of cancer. JAMA 1998, 280: 600.
59. Mickisch GH, Kossig J, Keilhauer G, et al.: Effects of calcium antagonists in multidrug resistant primary human renal cell carcinomas. Cancer Res 1990, 50: 3670-3674.
60. al-Shabanah OA, Osman AM, al-Harbi MM, et al.: Diltiazem potentiation of doxorubicin cytotoxicity and cellular uptake in Ehrlich ascites carcinoma cells. Chemotherapy 1995, 41: 368-377.
61. al-Gharably NM, Osman AM, al-Shabanah OA, et al.: Potentiation of doxorubicin cytotoxicity by the calcium channel blocker verapamil in Ehrlich ascites cells. Chemotherapy 1993, 39: 410-415.
62. Kunert-Radek J, Stepien H, Radek A, et al.: Inhibitory effect of calcium channel blockers on proliferation of human glioma cells in vitro. Acta Neurol Scand 1989, 79: 166-169.
63. Lee YS, Sayeed MM, Wurster RD: Intracellular Ca2+ mediates the cytotoxicity induced by bepridil and benzamil in human brain tumor cells. Cancer Lett 1995, 88: 87-91.
64. Raderer M, Scheithauer W: Clinical trials of agents that reverse multidrug resistance. A literature review. Cancer 1993, 72: 3553-3563.
65. Taylor JM, Simpson RU: Inhibition of cancer cell growth by calcium channel antagonists in the athymic mouse. Cancer Res 1992, 52: 2413-2418.
66. Rasmussen H, Barrett PQ: Calcium messenger system: an integrated view. Physiol Rev 1984, 64: 938-984.
67. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, et al.: Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). Lancet 1990, 335: 1109-1113.
68. Jonas M, Goldbourt U, Boyko V, et al.: Nifedipine and cancer mortality: ten-year follow-up of 2607 patients after acute myocardial infarction. Cardiovasc Drugs Ther 1998, 12: 177-181.
69. Hole DJ, Gillis CR, McCallum IR, et al.: Cancer risk of hypertensive patients taking calcium antagonists. J Hypertens 1998, 16: 119-124.
70. Borhani NO, Mercuri M, Borhani PA, et al.: Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA 1996, 276: 785-791.
71. Packer M, O'Connor CM, Ghali JK, et al., for the Prospective Randomized Amlodipine Survival Evaluation Study Group (PRAISE): Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996, 335: 1107-1114.
72. Gong L, Zhang W, Zhu Y, et al., with 11 collaborating centres in the Shangai area: Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996, 14: 1237-1245.
73. Liu L, Wang JG, Gong L, et al.: Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens 1998, 16(12 Pt 1): 1823-1829.
74. Staessen JA, Fagard R, Thijs L, et al.: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997, 350: 757-764.
75. Braun S, Boyko V, Behar S, et al.: Calcium channel blocking agents and risk of cancer in patients with coronary heart disease. Benzafibrate Infarction Prevention (BIP) study research group. J Am Coll Cardiol 1998, 31: 804-808.
76. Olsen JH, Toft Sorensen HT, Friis S, et al.: Cancer risk in users of calcium channel blockers. Hypertension 1997, 29: 1091-1094.
77. Brandenburg NA, Backstrom JT, Hinkle RL: Calcium channel blockers and cancer: the evidence against an association [letter]. Am J Hypertens 1996, 9(10 Pt 1): 1049-1050.
78. Stahl M, Bulpitt CJ, Palmer AJ, et al.: Calcium channel blockers, ACE inhibitors, and the risk of cancer in hypertensive patients: a report from the Department of Health Hypertension Care Computing Project (DHCCP). J Hum Hypertens 2000, 14: 299-304.
79. Meier CR, Derby LE, Jick SS, Jick H: Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer. Arch Intern Med 2000, 160: 349-353.
80. Vezina RM, Lesko SM, Rosenberg L, Shapiro S: Calcium channel blocker use and the risk of prostate cancer. Am J Hypertens 1998, 11: 1420-1425.
81. Sorensen HT, Olsen JH, Mellemkjaer L, et al.: Cancer risk and mortality in users of calcium channel blockers. A cohort study. Cancer 2000, 89: 165-170.
82. Cohen HJ, Pieper CF, Hanlon JT, et al.: Calcium channel blockers and cancer. Am J Med 2000, 108: 210-215.
83. Michels KB, Rosner BA, Walker AM, et al.: Calcium channel blockers, cancer incidence, and cancer mortality in a cohort of U.S. women: the nurses' health study. Cancer 1998, 83: 2003-2007.
84. Kanamasa K, Kimura A, Miyataka M, et al.: Incidence of cancer in postmyocardial infarction patients treated with short-acting nifedipine and diltiazem. Secondary Prevention Group. Cancer 1999, 85: 1369-1374.
85. Sajadieh A, Storm HH, Hansen JF: Verapamil and risk of cancer in patients with coronary artery disease. DAVIT Study Group. Danish Verapamil Infarction Trial. Am J Cardiol 1999, 83: 1419-1422.
86. Reddy MK, Baskaran K, Molteni A: Inhibitors of angiotensin-converting enzyme modulate mitosis and gene expression in pancreatic cancer cells. Proc Soc Exp Biol Med 1995, 210: 221-226.
87. Small W Jr, Molteni A, Kim YT, et al.: Captopril modulates hormone receptor concentration and inhibits proliferation of human mammary ductal carcinoma cells in culture. Breast Cancer Res Treat 1997, 44: 217-224.
88. Chen L, Re RN, Prakash O, Mondal D: Angiotensin-converting enzyme inhibition reduces neuroblastoma cell growth rate. Proc Soc Exp Biol Med 1991, 196: 280-283.
89. Ward WF, Molteni A, Ts'ao C, Hinz JM: The effect of Captopril on benign and malignant reactions in irradiated rat skin. Br J Radiol 1990, 63: 349-354.
90. Ward WF, Molteni A, Kim YT, et al.: captopril inhibits mitosis and growth of diethylnitrosamine-induced preneoplastic hepatic foci in F344 rats [abstract]. FASEB J 1992, 5: 6.
91. Bastiaens MT, Zwan NV, Verschueren GL, et al.: Three cases of pemphigus vegetans: induction by enalapril-association with internal malignancy. Int J Dermatol 1994, 33: 168-171.
92. Larbre JP, Nicolas JF, Collet P, et al.: Kaposi's sarcoma in a patient with rheumatoid arthritis possible responsibility of captopril in the development of lesions. J Rheumatol 1991, 18: 476-477.
93. Furness PN, Goodfield MJ, MacLennan KA, et al.: Severe cutaneous reactions to captopril and enalapril, histological study and comparison with early mycosis fungoides. J Clin Pathol 1986, 39: 902-907.
94. Puppin D Jr, Rybojad M, de la Chapelle C, Morel P: Kaposi's sarcoma associated with captopril [letter]. Lancet 1990, 336: 1251-1252.
95. Carroll J, Thaler M, Grossman E, et al.: Generalized pustular eruption associated with converting enzyme inhibitor therapy. Cutis 1995, 56: 276-278.
96. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991, 325: 293-302.
97. Maschio G, Alberti D, Janin G, et al.: Effect of the angiotensin- converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996, 334: 939-945.
98. Lever AF, Hole DJ, Gillis CR, et al.: Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998, 352: 179-184.
99. Weisenburger DD: Immunoblastic lymphadenopathy associated with methyldopa therapy: a case report. Cancer 1978, 42: 2322-2327.
100. Broden G, Bengtsson L: Biliary carcinoma associated with methyldopa therapy. Acta Chir Scand Suppl 1980, 500: 7-12.
101. Strom BL, Hibberd PL, Stolley PD: No evidence of association between methyldopa and biliary carcinoma. Int J Epidemiol 1985, 14: 86-90.
102. Kaufman DW, Kelly JP, Rosenberg L, et al.: Hydralazine and breast cancer. J Natl Cancer Inst 1987, 78: 243-246.
103. Kaufman DW, Kelly JP, Rosenberg L, et al.: Hydralazine use in relation to cancers of the lung, colon, and rectum. Eur J Clin Pharmacol 1989, 36: 259-264.